|
|
Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology to develop a pipeline of products designed to address the limitations of cell therapies. The following are the Company's clinical pipeline products: NiCord, which is evaluated in a Phase III study in patients with high-risk blood cancers as well as in a Phase SS study in patients with severe aplastic anemia, as well as NAM-NK, an innate immunotherapy for the treatment of hematologic and solid tumors, which is investigated in a Phase I investigator-sponsored trial for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL), and multiple myeloma (MM).
Number of employees : 168 people.
|
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
| Stock A |
1 |
60,021,415 |
41,901,966 |
69.8% |
75,117 |
0.1% |
69.8% |
|
|
|
| Name | Equities | % | | Clal Biotechnology Industries Ltd. | 9,744,857 |
16.2% | | Federated Global Investment Management Corp. | 5,128,300 |
8.55% | | Fidelity Management & Research Co. LLC | 4,587,704 |
7.65% | | Novartis AG | 4,336,759 |
7.23% | | Rock Springs Capital Management LP | 2,154,300 |
3.59% | | Wellington Management Co. LLP | 1,894,526 |
3.16% | | Elbit Imaging Ltd. | 1,828,373 |
3.05% | | I.H.C.V Israel Healthcare Ventures Ltd. | 1,782,847 |
2.97% | | Stonepine Capital Management LLC | 1,724,201 |
2.87% | | BVF Partners LP | 1,343,667 |
2.24% |
|
|
|
Sector Bio Therapeutic Drugs
| | 1st jan. | Capi. (M$) |
 | GAMIDA CELL LTD. | -15.75% | 128 |
| | | |
| GILEAD SCIENCES, INC. | -10.47% | 81 543 |
| REGENERON PHARMACEUTICALS, INC. | 9.40% | 74 440 |
| VERTEX PHARMACEUTICALS | 23.33% | 69 269 |
 | WUXI APPTEC CO., LTD. | -22.98% | 39 423 |
| BIONTECH SE | -40.00% | 37 588 |
 | GENMAB A/S | -19.73% | 19 850 |
 | ARGENX SE | -6.82% | 17 140 |
| BEIGENE, LTD. | -52.97% | 13 146 |
| NEUROCRINE BIOSCIENCES, INC. | 3.77% | 8 447 |
| HALOZYME THERAPEUTICS, INC. | 11.46% | 6 378 |
| LEGEND BIOTECH CORPORATION | -15.98% | 6 040 |
| SAREPTA THERAPEUTICS, INC. | -23.94% | 5 993 |
| EXELIXIS, INC. | -2.57% | 5 712 |
| INTRA-CELLULAR THERAPIES, INC. | 8.27% | 5 345 |
| ASCENDIS PHARMA A/S | -32.88% | 5 039 |
 | BIOCON LIMITED | -11.09% | 4 972 |
| MARAVAI LIFESCIENCES HOLDINGS, INC. | -18.35% | 4 500 |
| CEREVEL THERAPEUTICS HOLDINGS, INC. | -17.00% | 3 990 |
| ARROWHEAD PHARMACEUTICALS, INC. | -48.76% | 3 592 |
 | PHARMAESSENTIA CORPORATION | 21.84% | 3 394 |
Connections : Gamida Cell Ltd. |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
